[Prevalence of nocturia among people in Auxerre: the French part of the UrEpik study].

Objectives: To estimate the prevalence of nocturia among men and women aged 40 to 79 years old.

Material And Methods: A postal survey was carried out in a community-dwelling random sample in Auxerre, France. Nocturia was assessed using the item 7 of the International Prostate Symptom Score (IPSS).

[Portal vein aneurysm].

In a 72-year-old female patient suffering from non specific and vague abdominal pain, an aneurysm of the portal vein was discovered. In the absence of complication, and because the risk of operation appeared too high, the decision was to abstain from surgery. With more than 3 years of regular follow-up, the patient was free of symptoms, and the portal vein aneurysm was unchanged.

[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].

Objective: To compare, in general practice, the efficacy and safety of terazosin (5 mg per day in single dose) versus alfuzosin (7.5 mg per day in 3 doses) in patients with symptomatic benign prostatic hyperplasia (BPH) treated for 16 weeks.

Material And Methods: Thirteen investigators included patients over the age of 50 years presenting with BPH with an International Prostate Symptom Score (IPSS) greater than 12 and a post-voiding residual volume less than 300 ml.

Adjuvant treatment for failure of local radical therapy.

Adjuvant treatment is suitable where localised tumour recurrence justifies further treatment following failed radical prostatectomy. External beam radiotherapy is effective and may be enhanced by concomitant androgen deprivation therapy. Early adjuvant androgen deprivation therapy compared with 'deferred' therapy may drastically reduce morbidity and possibly increase survival in prostate cancer.

[Intracavernous injections].

Virag's paper concerning erection induced by intracavernous injection of papaverine was published 10 years ago, in 1982. Since this time, several substances have been tested; some have been abandoned, while others have demonstrated their efficacy and relative safety. After briefly recalling the physiology of erection and the principal substances used (papaverine, phentolamine, moxisylyte, PGE1, ceritine and VIP), the indications for intracavernous injection are reviewed in the context of investigation and treatment of certain forms of impotence.